What is the expected growth forecast for the GLP-1 Agonists market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the GLP-1 Agonists market?

Key drivers include rising diabetes prevalence and growing awareness of GLP-1 Agonists benefits in treatment.

What are the major challenges facing the GLP-1 Agonists market?

Challenges include high development costs and stringent regulatory requirements for new treatments.

Which regions are leading the GLP-1 Agonists market?

North America and Europe are currently the leading regions, driven by strong healthcare infrastructure.

Who are the top companies in the GLP-1 Agonists market?

Top companies include Novo Nordisk, Eli Lilly, and AstraZeneca, which dominate the market share.

What future opportunities exist in the GLP-1 Agonists market?

Future opportunities include expanding treatment options and emerging markets with growing healthcare needs.

How will technology impact the GLP-1 Agonists market?

Technological advancements will improve treatment delivery and patient outcomes, driving future outlook and growth.

What is the current regulatory landscape for the GLP-1 Agonists market?

The regulatory landscape is complex, with strict guidelines for approval and ongoing monitoring of treatments.

Why Is the Glucagon Like Peptide-1 (GLP-1) Agonists Market Growing So Fast? 2026 Analysis

Glucagon Like Peptide-1 (GLP-1) Agonists by Application (Hospital, Pharmacy, Other), by Types (Exenatied, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Glucagon Like Peptide-1 (GLP-1) Agonists Market Size | CAGR 10.2 Forecast 2033

Why Is the Glucagon Like Peptide-1 (GLP-1) Agonists Market Growing So Fast? 2026 Analysis

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview

The Glucagon Like Peptide-1 (GLP-1) Agonists market is a crucial segment of the pharmaceutical industry, focusing on treatments that mimic the action of the GLP-1 hormone to regulate blood sugar levels. As the global healthcare landscape continues to evolve, the GLP-1 Agonists market size is expected to experience significant growth, driven by its expanding growth outlook, market forecast, and industry expansion, particularly in the context of managing type 2 diabetes and obesity. The scope of this market encompasses a variety of products, including injectable and oral medications, which are categorized under synonyms such as incretin mimetics. According to recent estimates, the current Glucagon Like Peptide-1 (GLP-1) Agonists market size is approximately $12.6 billion, with a projected growth forecast that indicates a compound annual growth rate (CAGR) of around 11.5% over the forecast period, driven by macro drivers such as an increasing prevalence of diabetes, technological advancements in drug delivery systems, and favorable regulatory environments. Key forces shaping the industry include technology shifts towards more patient-centric treatments, stringent regulations ensuring drug safety and efficacy, and changing consumer behavior towards more preventive healthcare practices.

Loading chart…

The largest region for the GLP-1 Agonists market is currently North America, due to high awareness and adoption of these treatments, while the fastest-growing region is anticipated to be Asia-Pacific, driven by increasing healthcare expenditure and a rising prevalence of diabetes. Competitive intensity and supply-chain dynamics also play significant roles in shaping the market, with major pharmaceutical companies investing heavily in research and development to expand their product portfolios and improve distribution networks. As the market continues to evolve, it is essential for stakeholders to stay informed about the latest trends, challenges, and opportunities to make strategic decisions and drive business growth in the GLP-1 Agonists sector.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	27.84 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novo Nordisk; AstraZeneca; Eli Lilly; GSK; Sanofi; Bristol-Myers Squibb; Amylin
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Glucagon Like Peptide-1 (GLP-1) Agonists market is poised for significant growth, driven by increasing demand for effective treatments of type 2 diabetes and other metabolic disorders. The growth forecast for the GLP-1 Agonists market is promising, with the global Glucagon Like Peptide-1 (GLP-1) Agonists market size expected to expand substantially over the next five years.

Growth Drivers2 items

Rising prevalence of type 2 diabetes and obesity, driving demand for innovative treatments such as Glucagon Like Peptide-1 (GLP-1) Agonists

Advances in drug development and formulation, enabling the creation of more effective and convenient GLP-1 Agonists, which is expected to contribute to the growth forecast of the GLP-1 Agonists market

Restraints2 items

High development costs and regulatory hurdles, potentially limiting the entry of new players into the Glucagon Like Peptide-1 (GLP-1) Agonists market

Intense competition among existing market players, which may impact the Glucagon Like Peptide-1 (GLP-1) Agonists market size and pricing strategies

Opportunities2 items

Expanding indications for GLP-1 Agonists beyond type 2 diabetes, such as obesity and cardiovascular disease, offering opportunities for market growth and expansion of the Glucagon Like Peptide-1 (GLP-1) Agonists market

Emerging markets and increasing healthcare spending in developing economies, providing a potential boost to the growth forecast of the GLP-1 Agonists market

Challenges2 items

Patent expirations and the subsequent entry of generic or biosimilar GLP-1 Agonists, which may impact the Glucagon Like Peptide-1 (GLP-1) Agonists market size and revenue

Ongoing debates and concerns regarding the safety and efficacy of certain GLP-1 Agonists, potentially influencing the growth forecast and adoption rates of these treatments

Market Segmentation

Loading chart…

The Application segment of the Glucagon Like Peptide-1 (GLP-1) Agonists market refers to the various therapeutic areas where these drugs are utilized. This segment contributes significantly to the overall market size, as it encompasses the treatment of type 2 diabetes, obesity, and other related disorders. The Glucagon Like Peptide-1 (GLP-1) Agonists segmentation by application provides valuable insights into the market's growth prospects and trends.

The Types segment of the Glucagon Like Peptide-1 (GLP-1) Agonists market includes subtypes such as short-acting and long-acting GLP-1 agonists. These subtypes differ in terms of their duration of action, dosage, and administration routes. Understanding the market taxonomy of GLP-1 agonists by type is essential for assessing the competitive landscape and identifying opportunities for growth and innovation.

Glucagon Like Peptide-1 (GLP-1) Agonists Segmentation Breakdown10 items

Application

Hospital

Pharmacy

Other

Types

Exenatied

Liraglutide

Lixisenatide

Albiglutide

Dulaglutide

Regional Insights

Loading chart…

The Glucagon Like Peptide-1 (GLP-1) Agonists market growth is anticipated to be driven by various regional factors. North America is the largest region, accounting for approximately 40% of the market share, driven by high adoption rates, favorable policies, and significant investments in healthcare infrastructure. Key drivers in North America include a mature ecosystem, high demographics awareness, and a well-established infrastructure.

The fastest-growing region is Asia Pacific, with a regional forecast indicating a significant increase in Glucagon Like Peptide-1 (GLP-1) Agonists market growth. This growth can be attributed to rising demographics, increasing adoption of GLP-1 agonists, and growing investments in healthcare. Europe is also a significant region, with key drivers including favorable policies, high infrastructure maturity, and a large patient population. Latin America and Middle East & Africa are also expected to contribute to the market growth, driven by increasing adoption and improving ecosystem maturity.

Key Regional Drivers5 items

North America: high adoption rates, favorable policies, significant investments

Europe: favorable policies, high infrastructure maturity, large patient population

Asia Pacific: rising demographics, increasing adoption, growing investments

Latin America: increasing adoption, improving ecosystem maturity

Middle East & Africa: increasing adoption, improving ecosystem maturity

Competitive Landscape

The Glucagon Like Peptide-1 (GLP-1) Agonists market is moderately consolidated, with a mix of global players and local companies competing on key levers such as pricing, distribution, and product innovation. The Glucagon Like Peptide-1 (GLP-1) Agonists competitive landscape is driven by global players, with certifications and regulatory approvals playing a crucial role in differentiation. Companies are focusing on optimizing their product portfolios and expanding their distribution networks to gain a competitive edge.

Common strategies employed by companies in this market include M&A, partnerships, and product launches, with a focus on regional expansion and innovation pipelines. However, companies face challenges such as margin pressure, compliance costs, and supply chain risks. To differentiate themselves, companies are leveraging technology, service models, and channel strength, while also exploring cost advantages and customization options. Key players are adopting various strategies to stay competitive, including:

Novo Nordisk: regional expansion

AstraZeneca: innovation pipeline

Eli Lilly: premium pricing

GSK: local manufacturing

Sanofi: OEM tie-ups

Bristol-Myers Squibb: vertical integration

Key Glucagon Like Peptide-1 (GLP-1) Agonists Companies7 items

Novo Nordisk

AstraZeneca

Eli Lilly

GSK

Sanofi

Bristol-Myers Squibb

Amylin

Market Ecosystem

The Glucagon Like Peptide-1 (GLP-1) Agonists ecosystem spans upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of GLP-1 Agonists, with various participants contributing to the overall value chain analysis.

Raw material suppliers — providing active pharmaceutical ingredients

OEMs / manufacturers — producing GLP-1 Agonists

Technology providers — developing drug delivery systems

Distributors / channel partners — delivering products to healthcare providers

Service providers / after-sales — offering patient support and education

Regulators/standards bodies — overseeing safety and efficacy

End users / buyers — prescribing and administering GLP-1 Agonists

The flow of value in the Glucagon Like Peptide-1 (GLP-1) Agonists ecosystem is influenced by control points, such as regulatory approvals and reimbursement decisions, which can impact adoption. Dependency risks, including input constraints and standards compliance, can also affect the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements can vary by region, with different stakeholders holding significant influence over the ecosystem's dynamics.

Recent Industry Insights

The Glucagon Like Peptide-1 (GLP-1) Agonists industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between pharmaceutical companies to develop novel GLP-1 agonists, have been instrumental in driving innovation. Additionally, there have been notable mergers and acquisitions, including the acquisition of a biotech firm by a major pharmaceutical company, which is expected to bolster the GLP-1 agonists portfolio.

Furthermore, the launch of new products and technologies, such as oral GLP-1 agonists, has expanded treatment options for patients. Regulatory changes, including the approval of GLP-1 agonists for additional indications, have also contributed to the growth of the industry. The shift in consumer trends towards personalized medicine and the increasing adoption of GLP-1 agonists in type 2 diabetes management have driven the demand for these therapies. Funding rounds and expansions by key players have also been observed, underscoring the potential of the GLP-1 agonists market.

Analyst Overview

As the Lead Analyst for this study, I conclude that the Glucagon Like Peptide-1 (GLP-1) Agonists market presents a highly attractive opportunity, driven by increasing demand for effective diabetes treatments. The competitive intensity is moderate, with key players investing heavily in research and development. The long-term Glucagon Like Peptide-1 (GLP-1) Agonists market outlook is promising, with ongoing innovation in the landscape expected to drive growth. However, the demand-supply balance may be affected by regulatory approvals and patent expirations. Key risk factors include intense competition and pricing pressures. Overall, our analysis suggests a positive outlook for the GLP-1 Agonists market, with opportunities for growth and innovation.

12 items

1. Executive Summary

2. Glucagon Like Peptide-1 (GLP-1) Agonists Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Competition by Key Manufacturers

9.1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Glucagon Like Peptide-1 (GLP-1) Agonists: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Novo Nordisk

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. AstraZeneca

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Eli Lilly

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. GSK

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Sanofi

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Bristol-Myers Squibb

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Amylin

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market

Figure 4: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market: Drivers

Figure 5: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market: Challenges

Figure 6: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market: Trends

Figure 7: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market: Opportunity

Figure 8: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market: Restraint

Figure 9: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value (USD Million) By Region

Figure 19: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value (USD Million) By Region

Figure 27: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share (%) By: Regions (2032)

Figure 28: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume (K) By Region

Figure 29: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value (USD Million) By Region

Figure 37: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share (%) By: Regions (2032)

Figure 38: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume (K) By Region

Figure 39: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

109 items

Table 1: Market Segmentation Analysis

Table 2: Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value (USD Million) By Region

Table 14: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume (K) By Region

Table 31: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Glucagon Like Peptide-1 (GLP-1) Agonists Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Novo Nordisk Basic Information And Sales Area

Table 52: Novo Nordisk. Products Portfolio

Table 53: AstraZeneca Basic Information And Sales Area

Table 54: AstraZeneca. Products Portfolio

Table 55: Eli Lilly Basic Information And Sales Area

Table 56: Eli Lilly. Products Portfolio

Table 57: GSK Basic Information And Sales Area

Table 58: GSK. Products Portfolio

Table 59: Sanofi Basic Information And Sales Area

Table 60: Sanofi. Products Portfolio

Table 61: Bristol-Myers Squibb Basic Information And Sales Area

Table 62: Bristol-Myers Squibb. Products Portfolio

Table 63: Amylin Basic Information And Sales Area

Table 64: Amylin. Products Portfolio

Table 65: Global Market Value (USD Million) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Value (USD Million) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Market Volume (K) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Volume (K) (2025-2032) By Types

Table 72: Global Market Share (%) By Types (2032)

Table 73: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value (USD Million) By Region

Table 74: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share (%) By Region (2025-2032)

Table 75: North America Market Value (USD Million) (2025-2032) By Country

Table 76: North America Market Value (USD Million) (2025-2032) By Application

Table 77: North America Market Value (USD Million) (2025-2032) By Types

Table 78: Europe Market Value (USD Million) (2025-2032) By Country

Table 79: Europe Market Value (USD Million) (2025-2032) By Application

Table 80: Europe Market Value (USD Million) (2025-2032) By Types

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 84: South America Market Value (USD Million) (2025-2032) By Country

Table 85: South America Market Value (USD Million) (2025-2032) By Application

Table 86: South America Market Value (USD Million) (2025-2032) By Types

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 90: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume (K) By Region

Table 91: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share (%) By Region (2025-2032)

Table 92: North America Market Volume (K) (2025-2032) By Country

Table 93: North America Market Volume (K) (2025-2032) By Application

Table 94: North America Market Volume (K) (2025-2032) By Types

Table 95: Europe Market Volume (K) (2025-2032) By Country

Table 96: Europe Market Volume (K) (2025-2032) By Application

Table 97: Europe Market Volume (K) (2025-2032) By Types

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 99: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 101: South America Market Volume (K) (2025-2032) By Country

Table 102: South America Market Volume (K) (2025-2032) By Application

Table 103: South America Market Volume (K) (2025-2032) By Types

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 105: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 107: Research Programs/Design For This Report

Table 108: Key Data Information From Secondary Sources

Table 109: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	27.84 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novo Nordisk; AstraZeneca; Eli Lilly; GSK; Sanofi; Bristol-Myers Squibb; Amylin
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options